![](https://monteverdelaw.com/wp-content/uploads/case-logo/iveric-bio-inc.png)
IVERIC bio, Inc. (NASDAQ: ISEE), relating to its proposed sale to Astellas Pharma Inc. Under the terms of the agreement, ISEE shareholders are expected to receive $40.00 in cash per share they own.
IVERIC bio, Inc. (NASDAQ: ISEE), relating to its proposed sale to Astellas Pharma Inc. Under the terms of the agreement, ISEE shareholders are expected to receive $40.00 in cash per share they own.